The global catheter-directed thrombolysis market is estimated to garner a revenue of ~USD 812 Million by the end of 2031 by growing at a CAGR of ~10% over the forecast period, i.e., 2022 – 2031. Further, the market generated a revenue of ~USD 336 Million in the year 2021. The growth of the market is primarily attributed to the increasing prevalence of pulmonary embolism and deep vein thrombosis (DVT) amidst increasing number of stroke issues. For instance, every year approximately 900,010 number of people affected by deep vein thrombosis (DVT) or pulmonary embolism (PE).
Get more information on this report: Request Sample PDF
Catheter-directed thrombolysis is a prominent treatment to treat blood vessel clots by improving blood flow and deterring tissue damage. Thrombolysis is a sort of minimally invasive endovascular therapy. It primarily includes injecting clot-busting drugs through an intravenous (IV) line or a catheter-directed thrombolysis (CDT) device, which supplies the drugs directly to the blocking sites for anticoagulation. Catheter-directed thrombolysis device consists an X-Ray camera, catheter, special medicines, and a medical device used to disperse blood clots. CDT devices are safer than traditional surgical intervention such as surgical balloon thrombectomy, allowing for shorter hospital stays while reducing patient trauma and health issues.As per the data provided by the National Center for Biotechnology Information, trauma is the major cause of death among young adults and accounts for 10% of all deaths in men and women. Every year, approximately 50 million people visit the emergency department in the United States owing to trauma.
The global catheter-directed thrombolysismarket is segmented and analyzed for demand and supply by end-user intoambulatory surgical centers, hospitals, radiology clinics, and others. Out of these, hospitals segment is estimated to significantly grow over the forecast period owing to theincreasing number of patients of pulmonary embolism, and deep vein thrombosis, and increasing government investments in healthcare sector. Asper the data by the World Bank, the world-wide health expenditure in 2019 was grown to 9.83%.
According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capitaexpenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.
Regionally, the global catheter-directed thrombolysis market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Amongst these markets, the market in North America is projected to hold the largest market share by the end of 2031 backed by the availability of advanced healthcare facilities, increase in healthcare expenditure, and growing disposable incomein the region.According to the data released by the Centers for Medicare & Medicaid Services (CMS), in 2020, US national healthcare expenditure expanded 9.7% to USD 4.1 trillion, equivalent to USD 12,530 per person, representing for 19.7% of Gross Domestic Product.
The global catheter-directed thrombolysis market is further classified on the basis of region as follows:
Our in-depth analysis of the global catheter-directed thrombolysis market includes the following segments:
By Delivery Mode
Top Featured Companies Dominating the Global Catheter-Directed Thrombolysis Market
FREQUENTLY ASKED QUESTIONS
Increased prevalence of obesity, growing number of strokes, upsurge in chronic diseases, and increasing chronic kidney disease are some major factors driving the growth of the market.
The market is anticipated to attain a CAGR of ~10% over the forecast period, i.e., 2022 – 2031.
Shortage of advanced healthcare infrastructure in developing countries, risk coupled with the catheter-directed thrombolysis, and lack of knowledge about the procedureare estimated to hamper the market growth.
The market in North America is projected to hold the largest market share by the end of 2031 and provide more business opportunities in the future.
The major players in the market are Boston Scientific Corporation (BSC), Inari Medical, Inc.AngioDynamics, Inc.Ivascular, S.L.U, Teleflex Incorporated, Penumbra, Inc., Thrombolex, Inc., Medtronic, BrosMed Medical Co.
The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by delivery mode, indication, end-user, and by region.
The hospitals segment is anticipated to garner the largest market size by the end of 2031 and display significant growth opportunities.
Select License Type
Direct access to analyst to help you understand the market in a better way to handle your critical question
Citing your business specific requirement our consultant would assist you ensuring targeted goal is achieved
Get 10% free customization